Literature DB >> 19997838

[Erectile dysfunction].

Brigitte Esterbauer1, Andreas Jungwirth.   

Abstract

Erectile Dysfunction is one of the most prevalent sexual disorders in men. According to the current literature the prevalence is about 16% for all men. The diagnostic workup of a patient suffering from E.D. is a detailed anamnesis, a physical and endocrinological evaluation and the suggestion of the optimal therapeutic treatment. The therapeutic application of PDE-5 inhibitors has made the therapy of E.D. much easier. It is a safe and highly efficient therapeutic option. But man must not forget that in severe cases of erectile dysfunction, the application of SKAT therapy, penile implants or vacuum devices might be necessary. Since a functioning sex life is important not only for the men, but also for the couple, a more open attitude of us, physicians, is desirable to help more men who suffer from this sexual dysfunction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19997838     DOI: 10.1007/s10354-009-0719-z

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  28 in total

1.  Is the metabolic syndrome an independent risk factor for erectile dysfunction?

Authors:  Stefan Heidler; Christian Temml; Clemens Broessner; Karl Mock; Michael Rauchenwald; Stephan Madersbacher; Anton Ponholzer
Journal:  J Urol       Date:  2007-02       Impact factor: 7.450

2.  Prevalence and risk factors for erectile dysfunction in the US.

Authors:  Elizabeth Selvin; Arthur L Burnett; Elizabeth A Platz
Journal:  Am J Med       Date:  2007-02       Impact factor: 4.965

3.  Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction.

Authors:  B Davis-Joseph; L Tiefer; A Melman
Journal:  Urology       Date:  1995-03       Impact factor: 2.649

4.  The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial.

Authors:  H Porst; R Rosen; H Padma-Nathan; I Goldstein; F Giuliano; E Ulbrich; T Bandel
Journal:  Int J Impot Res       Date:  2001-08       Impact factor: 2.896

5.  AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients.

Authors:  F Montorsi; P Rigatti; G Carmignani; C Corbu; B Campo; G Ordesi; G Breda; P Silvestre; B Giammusso; G Morgia; A Graziottin
Journal:  Eur Urol       Date:  2000-01       Impact factor: 20.096

6.  Erectile dysfunction is a marker for cardiovascular complications and psychological functioning in men with hypertension.

Authors:  M Burchardt; T Burchardt; A G Anastasiadis; A J Kiss; A Shabsigh; A de La Taille; R V Pawar; L Baer; R Shabsigh
Journal:  Int J Impot Res       Date:  2001-10       Impact factor: 2.896

7.  Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease.

Authors:  Francesco Montorsi; Alberto Briganti; Andrea Salonia; Patrizio Rigatti; Alberto Margonato; Andrea Macchi; Stefano Galli; Paolo M Ravagnani; Piero Montorsi
Journal:  Eur Urol       Date:  2003-09       Impact factor: 20.096

Review 8.  Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters.

Authors:  Robert A Kloner
Journal:  Clin Cardiol       Date:  2004-04       Impact factor: 2.882

9.  The place of surgery for vascular impotence in the third millennium.

Authors:  Eric Wespes; Thierry Wildschutz; Thierry Roumeguere; Claude C Schulman
Journal:  J Urol       Date:  2003-10       Impact factor: 7.450

10.  Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.

Authors:  O I Linet; F G Ogrinc
Journal:  N Engl J Med       Date:  1996-04-04       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.